177 related articles for article (PubMed ID: 19158050)
1. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia.
Habra MA; Jimenez C; Huang SC; Cote GJ; Murphy WA; Gagel RF; Hoff AO
Endocr Pract; 2008 Dec; 14(9):1108-14. PubMed ID: 19158050
[TBL] [Abstract][Full Text] [Related]
2. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
3. Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia.
Imanishi Y; Hashimoto J; Ando W; Kobayashi K; Ueda T; Nagata Y; Miyauchi A; Koyano HM; Kaji H; Saito T; Oba K; Komatsu Y; Morioka T; Mori K; Miki T; Inaba M
J Bone Miner Metab; 2012 Jan; 30(1):93-9. PubMed ID: 21739089
[TBL] [Abstract][Full Text] [Related]
4. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.
Rowe PS; de Zoysa PA; Dong R; Wang HR; White KE; Econs MJ; Oudet CL
Genomics; 2000 Jul; 67(1):54-68. PubMed ID: 10945470
[TBL] [Abstract][Full Text] [Related]
5. The wrickkened pathways of FGF23, MEPE and PHEX.
Rowe PS
Crit Rev Oral Biol Med; 2004 Sep; 15(5):264-81. PubMed ID: 15470265
[TBL] [Abstract][Full Text] [Related]
6. Paraneoplastic Secretion of Multiple Phosphatonins From a Deep Fibrous Histiocytoma Causing Oncogenic Osteomalacia.
Leow MKS; Dogra S; Ge X; Chuah KL; Liew H; Loke KSH; McFarlane C
J Clin Endocrinol Metab; 2021 Apr; 106(5):e2299-e2308. PubMed ID: 33462615
[TBL] [Abstract][Full Text] [Related]
7. "Phosphatonins" and the regulation of phosphorus homeostasis.
Berndt TJ; Schiavi S; Kumar R
Am J Physiol Renal Physiol; 2005 Dec; 289(6):F1170-82. PubMed ID: 16275744
[TBL] [Abstract][Full Text] [Related]
8. Regulation of mRNA expression of matrix extracellular phosphoglycoprotein (MEPE)/ osteoblast/osteocyte factor 45 (OF45) by fibroblast growth factor 2 in cultures of rat bone marrow-derived osteoblastic cells.
Zhang GX; Mizuno M; Tsuji K; Tamura M
Endocrine; 2004 Jun; 24(1):15-24. PubMed ID: 15249699
[TBL] [Abstract][Full Text] [Related]
9. What have we learnt about the regulation of phosphate metabolism?
Blumsohn A
Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):397-401. PubMed ID: 15199289
[TBL] [Abstract][Full Text] [Related]
10. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia.
Bahrami A; Weiss SW; Montgomery E; Horvai AE; Jin L; Inwards CY; Folpe AL
Am J Surg Pathol; 2009 Sep; 33(9):1348-54. PubMed ID: 19609206
[TBL] [Abstract][Full Text] [Related]
11. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23.
White KE; Larsson TE; Econs MJ
Endocr Rev; 2006 May; 27(3):221-41. PubMed ID: 16467171
[TBL] [Abstract][Full Text] [Related]
12. Tumor induced osteomalacia: associated with elevated circulating levels of fibroblast growth factor-7 in addition to fibroblast growth factor-23.
Bansal S; Khazim K; Suri R; Martin D; Werner S; Fanti P
Clin Nephrol; 2016 Jan; 85(1):57-62. PubMed ID: 26521888
[TBL] [Abstract][Full Text] [Related]
13. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
Pereira RC; Juppner H; Azucena-Serrano CE; Yadin O; Salusky IB; Wesseling-Perry K
Bone; 2009 Dec; 45(6):1161-8. PubMed ID: 19679205
[TBL] [Abstract][Full Text] [Related]
14. Phosphate diabetes, tubular phosphate reabsorption and phosphatonins.
Laroche M; Boyer JF
Joint Bone Spine; 2005 Oct; 72(5):376-81. PubMed ID: 16214071
[TBL] [Abstract][Full Text] [Related]
15. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism.
Sommer S; Berndt T; Craig T; Kumar R
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):497-503. PubMed ID: 17224271
[TBL] [Abstract][Full Text] [Related]
16. Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases.
Rendina D; De Filippo G; Tauchmanovà L; Insabato L; Muscariello R; Gianfrancesco F; Esposito T; Cioffi M; Colao A; Strazzullo P; Mossetti G
Calcif Tissue Int; 2009 Oct; 85(4):293-300. PubMed ID: 19763378
[TBL] [Abstract][Full Text] [Related]
17. Matrix extracellular phosphoglycoprotein inhibits phosphate transport.
Marks J; Churchill LJ; Debnam ES; Unwin RJ
J Am Soc Nephrol; 2008 Dec; 19(12):2313-20. PubMed ID: 19005008
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin.
Fukumoto S; Yamashita T
Curr Opin Nephrol Hypertens; 2002 Jul; 11(4):385-9. PubMed ID: 12105387
[TBL] [Abstract][Full Text] [Related]
19. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone.
Argiro L; Desbarats M; Glorieux FH; Ecarot B
Genomics; 2001 Jun; 74(3):342-51. PubMed ID: 11414762
[TBL] [Abstract][Full Text] [Related]
20. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
